Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LuX: A Feasibility Study of Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

NCT07737925 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT07737925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07737925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LuX: A Feasibility Study of Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2031
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate resistant prostate cancer, prostate cancer